Clinical trial
Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides
NCT00365937 · Cliniques universitaires Saint-Luc- Université Catholique de Louvain, Other · Terminated
Key facts
| NCT number | NCT00365937 |
|---|---|
| Title | Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides |
| Official title | Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides |
| Lead sponsor | Cliniques universitaires Saint-Luc- Université Catholique de Louvain, Other |
| Collaborators | Immutep S.A.S. Industry |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Biological |
| Interventions | Immunological peptides and immunological adjuvants, HLA-A2 peptides, Montanide ISA51, IMP321 |
| Enrollment | 19 |
| Start date | Aug 1, 2006 |
| Primary completion | Dec 13, 2013 |
| Completion | Dec 13, 2013 |
| First posted | Aug 18, 2006 |
| Last update posted | Mar 6, 2019 |
| Countries | Belgium |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: